Investigational Drug Targets Sleep Apnea and Nocturnal Hypertension
A phase 2 trial will evaluate the drug’s potential to reduce upper airway obstruction and nocturnal hypertension in patients with moderate-to-severe OSA.
A phase 2 trial will evaluate the drug’s potential to reduce upper airway obstruction and nocturnal hypertension in patients with moderate-to-severe OSA.
In a new analysis, investigators probed multiple exercise response patterns before and after exposure to the drug in patients with hypertrophic obstructive cardiomyopathy.
Researchers have identified the specific immune cells that drive cardiac inflammation in patients taking the chemotherapy drug doxorubicin.
Read MoreDespite new guidelines, millions of older adults continue to use aspirin for primary prevention of cardiovascular disease.
Read MoreA study unveils unexpected mechanisms of SGLT2 inhibitors, challenging the assumption that their beneficial, organ-protective effects stem from a diuretic effect.
Read MoreA clinical trial found that an investigational drug improved exercise capacity in patients with hypertrophic cardiomyopathy by increasing their peak oxygen uptake.
Read MoreThe weight loss drug also positively impacts symptoms, physical limitations, and body weight in HFpEF patients.
Read MoreResearch presented at the ESC’s annual congress shows a significant survival benefit for heart failure patients who receive COVID-19 vaccinations.
Read MoreA new study in mice suggests regular use of acetaminophen, the active ingredient in Tylenol and many other pain medications, at moderate to high doses may pose a risk to heart health.
Read MoreAprocitentan, targeting the endothelin pathway, offers a new approach for managing hypertension alongside existing medications.
Read MoreA poll finds more than half of people aged 50 to 80 taking aspirin don’t have cardiovascular disease. For some, this means low preventive benefit and bleeding risks.
Read More